Physicians from university hospitals or other research facilities involving patient healthcare in Germany can apply
- who have attained outstanding achievements in research, patient healthcare and teaching
- who have undergone a Clinician Scientist program or are able to prove a leave of absence from clinical responsibilities for purposes of research lasting at least one year
- who are pursuing an innovative, convincing and internationally competitive scientific work program
- who were born in 1981 and thereafter. This age limit can be raised in justified individual cases to be clarified with the foundation in advance due to family commitments (such as pregnancy, parental leave or caring for relatives), military service or alternate mandatory service in lieu of military service, or issues of a comparable nature.
On the part of the accepting university hospital and medical faculty thereof, prerequisite for an application is:
- the contractually designated time for research amounting to 50% of working hours to the benefit of the research share of the professorship
- the continued employment and assumption of personnel expenses for the patient healthcare share (50% of working hours) at the level commensurate with experience as per the collective bargaining agreement for physicians (“TVÄ”), including allowances
- that the title as professor acts preferentially toward appointment to a “W-Professorship” (official German salary scale), at least for the term of the Clinician Scientist Professorship
- the provision of possibilities within the organization and infrastructure (such as clinical position, staff, spaces for research, lab equipment) for successful implementation of a Clinician Scientist function.
Post-doctoral teaching qualification is not a condition, completed advanced training as a medical specialist is expected.
Please always take note of our current calls for applications/proposals for this line of funding. You can find them in the menu “Current Topics” under Call for Proposals.
Announcement of Clinician Scientist Professorships 2020
Else Kröner Clinician Scientist Professorship: Deciphering the impact of amino acid metabolism on intestinal immunity and chronic inflammation
Konrad Aden is interested in the molecular pathophysiology of inflammatory bowel disease(IBD). IBD is characterized by fundamental disturbance of the amino acid metabolism, but the underlying molecular cause remains elusive. The aim of his research is to decipher the cause and consequences of disrupted amino acid immunometabolism and to translate key molecular findings into novel diagnostic and therapeutic approaches in the management of IBD.
Else Kröner Clinician Scientist Professorship: Neurogenic Dysphagia - Pathophysiology, Diagnosis und Innovative Therapeutic Strategies
The act of swallowing is a complex sensorimotor function which is processed in a distributed neural network. Therefore, disturbance of swallowing function (dysphagia) is a prevalent symptom of many neurological diseases, e.g. stroke. Dysphagia leads to major complications such as airway infections, malnutrition and long-time dependency on a feeding tube. Evidence-based treatment options are still limited. PD Dr. Sonja Suntrup-Krüger’s scientific interest is in the brain control mechanisms of swallowing in health and disease and neurostimulation methods to enhance dysphagia rehabilitation. She wants to get new insights into neuroplasticity mechanisms of the brain with functional neuroimaging to further optimize these innovative treatment strategies.
Else Kröner Clinician Scientist Professorship: Cardiovascular Systems Immunology
Cells of the adaptive immune system, T and B lymphocytes, protect against viruses and bacteria during infection. In autoimmune disease, however, autoreactive immune cells recognize endogenous proteins and destruct tissues and organs. Atherosclerosis is a chronic inflammatory disease of arteries that lead to the build-up of vessel-occluding plaques and causes myocardial infarction and stroke. Atherosclerosis is understood as partial autoimmune disease as autoreactive, pathogenic immune cells can be found in atherosclerotic arteries. As part of his professorship, Wolf aims to systematically describe the cellular immune response in patients with atherosclerotic disease. His work may lead to the development of novel diagnostic and therapeutic strategies in immune-mediated cardiovascular disease.
Announcement of Clinician Scientist Professorships 2019
Else Kröner Clinician Scientist Professship: Translational Immunodermatology
The congenital immune system shields the body against infiltrators such as bacteria or viruses, although what often occurs in the process is “collateral damage”, for instance excessive inflammatory responses. The system also plays a decisive role in the case of tumor diseases and autoimmunity. “We are studying the congenital immune system’s defense mechanisms and developing therapies against its dysregulation,” is how Erpenbeck explains her professorship.
PD Dr. Luise Erpenbeck studied medicine at the Otto von Guericke University of Magdeburg and the Georg August University of Göttingen. She prepared her doctoral dissertation at the Rudolf Virchow Center for Experimental Biomedicine in Würzburg, and received her doctorate in 2011. She was subsequently active as intern and research scientist at the Clinic for Dermatology, Venereology and Allergology at University Medical Center Göttingen. This was followed by a 2-year research period abroad as scientist (post-doctoral) at the Harvard Medical School in Boston, USA. As her next step she established a third-party-funded research group within the Clinic for Dermatology in Göttingen. She successfully passed the German specialist certification exam for dermatology, venereology and allergology in 2019. Since September 2019 she functions in a capacity as specialist and head of the department for Translational Interdisciplinary Medicine at the Dermatology Clinic of the University of Göttingen. Her post-doctoral teaching qualification occurred in 2020 at the university in Göttingen.
Else Kröner Clinician Scientist Professorship: Translational Pancreatic Surgery
Ihsan Ekin Demir researches the influence of the nervous system on the origin and progression of pancreatic cancer. In nearly 100 percent of the cases, tumor cells from the pancreas invade nerves and use them to spread the tumor at an early stage. Within the course of the professorship Demir wants to develop new molecular therapy strategies against this so-called “neural invasion”.
PD Dr. Ihsan Ekin Demir, Ph.D. studied medicine at the Ruprecht Karl University of Heidelberg and at the Technical University of Munich. He received his degree in medicine in 2011 in Munich. He subsequently worked as intern at the Clinic and Polyclinic for Surgery (Director: Univ.-Prof. Dr. H. Friess) of the “Klinikum rechts der Isar”, the university hospital at the TU Munich, and successfully completed his advanced training as a medical specialist for visceral surgery in 2016. During the specialist training he also completed the PhD program at the TU Munich to be able to continue to work as a scientist alongside his clinical activity. He acquired his post-doctoral teaching qualification in 2016 in Munich. Since 2019 he functions in a capacity as chief resident at the Clinic and Polyclinic for Surgery of the “Klinikum rechts der Isar” and heads the Pancreas Research Laboratory at the Clinic for Surgery. In 2019 he was honored with the acclaimed Rising Star Award from the United European Gastroenterology (UEG) organization.
Else Kröner Clinician Scientist Professorship: Approaches in artificial intelligence toward establishing personalized and targeted therapies for leukemias and lymphomas
Sascha Dietrich pursues the goal to predict the best suitable therapy for patients with forms of leukemia and lymphomas, and to avoid the detrimental side effects of an ineffective therapy. To accomplish this, tumor cells at different levels are characterized in a highly detailed manner and linked with clinical progression using “artificial intelligence” methods to enable individual predictions to be made regarding the response to therapy.
PD Dr. Sascha Dietrich concluded his studies in medicine and received his M.D. from the Friedrich Schiller University of Jena in 2008. Within the course of his advanced training as a medical specialist for internal medicine and hematology-oncology at Heidelberg University Hospital he specialized in lymphoid malignancies and cellular therapeutic treatments such as allogeneic stem cell transplantation. In addition to training as an internist he attained qualification as an emergency physician in 2011. Subsequent to specialist training, in 2014 he completed a 2-year post-doctoral training program in bioinformatics at the European Molecular Biology Laboratory (EMBL) in Heidelberg. In 2016 he was appointed chief resident at the Clinic for Hematology, Oncology and Rheumatology in Heidelberg. Since 2016 he is group leader of the junior research group in the field of systemic medicine, which is supported by BMBF, the German Federal Ministry of Education and Research. Since 2017 he also functions in a capacity as group leader for the Molecular Medicine Partnership Unit. He acquired his post-doctoral teaching qualification at the university in Heidelberg in 2017.